开云app官网登录入口网页版-官方正版

#PFS#

70篇内容 | 2102人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1448693, encodeId=10d21448693df, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ESMO 2022：Nirogacestat改善了进展性硬纤维瘤患者的PFS（DeFi研究）, objectType=article, longId=739075, objectId=1b78e39075cc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b78e39075cc, replyNumber=0, likeNumber=122, createdTime=2022-09-13, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b78e39075cc, moduleTitle=ESMO 2022：Nirogacestat改善了进展性硬纤维瘤患者的PFS（DeFi研究）, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1b78e39075cc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448692, encodeId=be7514486922c, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ESMO 2022：内分泌抵抗性ER阳性晚期乳腺癌中，Amcenestrant的PFS结果与内分泌治疗相当, objectType=article, longId=739073, objectId=814ce3907329, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=814ce3907329, replyNumber=0, likeNumber=98, createdTime=2022-09-13, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=814ce3907329, moduleTitle=ESMO 2022：内分泌抵抗性ER阳性晚期乳腺癌中，Amcenestrant的PFS结果与内分泌治疗相当, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=814ce3907329)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448691, encodeId=9bd1144869160, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=BMC Cancer：幽门螺杆菌能影响晚期胃癌免疫治疗结局？PFS和OS均可相差3倍！, objectType=article, longId=737086, objectId=06e5e370861c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06e5e370861c, replyNumber=0, likeNumber=80, createdTime=2022-08-28, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06e5e370861c, moduleTitle=BMC Cancer：幽门螺杆菌能影响晚期胃癌免疫治疗结局？PFS和OS均可相差3倍！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=06e5e370861c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448690, encodeId=73b014486908f, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！, objectType=article, longId=729096, objectId=317ae2909688, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=317ae2909688, replyNumber=0, likeNumber=112, createdTime=2022-06-12, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=317ae2909688, moduleTitle=ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=317ae2909688)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448689, encodeId=6f951448689d8, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ASCO 2022 | ASCENT临床大胜收官：面对「老大难」mTNBC，戈沙妥珠单抗实现OS/PFS双获益！, objectType=article, longId=728854, objectId=1528e28854ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1528e28854ea, replyNumber=0, likeNumber=100, createdTime=2022-06-09, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1528e28854ea, moduleTitle=ASCO 2022 | ASCENT临床大胜收官：面对「老大难」mTNBC，戈沙妥珠单抗实现OS/PFS双获益！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=1528e28854ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448688, encodeId=e3b614486885c, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, objectType=article, longId=727788, objectId=2cfae27788c8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2cfae27788c8, replyNumber=0, likeNumber=101, createdTime=2022-05-26, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2cfae27788c8, moduleTitle=J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=2cfae27788c8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448687, encodeId=e51b144868ea5, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS, objectType=article, longId=727473, objectId=6721e274735c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6721e274735c, replyNumber=0, likeNumber=101, createdTime=2022-05-22, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6721e274735c, moduleTitle=Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=6721e274735c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448686, encodeId=5062144868698, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=罗氏PD-L1+TIGIT一线治疗NSCLC，期中分析发现PFS未获益，仍然期待OS终点的数据表现, objectType=article, longId=726686, objectId=ead0e2668637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ead0e2668637, replyNumber=0, likeNumber=0, createdTime=2022-05-13, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ead0e2668637, moduleTitle=罗氏PD-L1+TIGIT一线治疗NSCLC，期中分析发现PFS未获益，仍然期待OS终点的数据表现, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=ead0e2668637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448685, encodeId=b81d1448685db, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, objectType=article, longId=302295, objectId=5d50302295d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d50302295d1, replyNumber=0, likeNumber=92, createdTime=2022-04-04, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d50302295d1, moduleTitle=PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=5d50302295d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448684, encodeId=79d3144868469, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, objectType=article, longId=300705, objectId=242e300e0568, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=242e300e0568, replyNumber=0, likeNumber=95, createdTime=2022-03-15, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=242e300e0568, moduleTitle=Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=242e300e0568)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448683, encodeId=2d401448683ec, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS, objectType=article, longId=299277, objectId=87e42992e798, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87e42992e798, replyNumber=0, likeNumber=118, createdTime=2022-02-22, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87e42992e798, moduleTitle=Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=87e42992e798)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448682, encodeId=5dbd144868250, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS, objectType=article, longId=293561, objectId=cf2c293561b4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf2c293561b4, replyNumber=0, likeNumber=83, createdTime=2022-01-09, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf2c293561b4, moduleTitle=J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=cf2c293561b4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448681, encodeId=a9031448681e5, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=Front Oncol：既往接受过抗血管治疗可能影响后线安罗替尼治疗晚期肺癌的PFS，但不影响OS和ORR, objectType=article, longId=292663, objectId=79a729266362, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=79a729266362, replyNumber=0, likeNumber=85, createdTime=2021-12-25, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=79a729266362, moduleTitle=Front Oncol：既往接受过抗血管治疗可能影响后线安罗替尼治疗晚期肺癌的PFS，但不影响OS和ORR, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=79a729266362)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448680, encodeId=2f151448680bd, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=Nat Med：PfSPZ疫苗对婴儿疟疾的安全性、免疫原性和有效性：一项双盲、随机、安慰剂对照的2期试验 , objectType=article, longId=217120, objectId=9c0421e12073, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9c0421e12073, replyNumber=0, likeNumber=86, createdTime=2021-09-16, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9c0421e12073, moduleTitle=Nat Med：PfSPZ疫苗对婴儿疟疾的安全性、免疫原性和有效性：一项双盲、随机、安慰剂对照的2期试验 , moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=9c0421e12073)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448679, encodeId=63be14486e94d, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=PFS：激光辅助治疗面部填充物并发症后，采用脂肪填充的效果甚好！, objectType=article, longId=208412, objectId=8463208412e6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8463208412e6, replyNumber=0, likeNumber=95, createdTime=2021-03-16, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8463208412e6, moduleTitle=PFS：激光辅助治疗面部填充物并发症后，采用脂肪填充的效果甚好！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8463208412e6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448678, encodeId=9b6f14486e8bc, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=PFS：10年随访结果出炉！记忆凝胶植入物用于隆胸或乳房再造安全有效, objectType=article, longId=208392, objectId=a7812083925b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a7812083925b, replyNumber=0, likeNumber=84, createdTime=2021-03-16, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a7812083925b, moduleTitle=PFS：10年随访结果出炉！记忆凝胶植入物用于隆胸或乳房再造安全有效, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a7812083925b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448677, encodeId=d2ef14486e73c, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=PFS 翻倍！tipifarnib获FDA突破性疗法资格, objectType=article, longId=207639, objectId=531020e6394d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=531020e6394d, replyNumber=0, likeNumber=88, createdTime=2021-02-28, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=531020e6394d, moduleTitle=PFS 翻倍！tipifarnib获FDA突破性疗法资格, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=531020e6394d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448676, encodeId=3dc314486e67b, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS, objectType=article, longId=207552, objectId=b86b20e552cf, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b86b20e552cf, replyNumber=0, likeNumber=85, createdTime=2021-02-26, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b86b20e552cf, moduleTitle=JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=b86b20e552cf)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448675, encodeId=165014486e597, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=ASCO GU 2021: DPP4抑制剂对糖尿病合并前列腺癌患者PFS的影响, objectType=article, longId=207263, objectId=8b0220e263c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8b0220e263c4, replyNumber=0, likeNumber=88, createdTime=2021-02-20, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8b0220e263c4, moduleTitle=ASCO GU 2021: DPP4抑制剂对糖尿病合并前列腺癌患者PFS的影响, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=8b0220e263c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1448674, encodeId=389314486e436, content=<a href='/topic/show?id=aaf21412e7e' target=_blank style='color:#2F92EE;'>#PFS#</a>, objectTitle=PFS、ORR翻倍，死亡风险降低40%！FDA批准卡博替尼联合Opdivo一线治疗肾癌, objectType=article, longId=206244, objectId=febb2062446f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=febb2062446f, replyNumber=0, likeNumber=91, createdTime=2021-01-27, rootId=0, userName=jeanqiuqiu, userId=47f75418389, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=febb2062446f, moduleTitle=PFS、ORR翻倍，死亡风险降低40%！FDA批准卡博替尼联合Opdivo一线治疗肾癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=febb2062446f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

PFS

2020-05-29

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ESMO 2022：Nirogacestat改善了进展性硬纤维瘤患者的PFS（DeFi研究）

2022-09-13

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ESMO 2022：内分泌抵抗性ER阳性晚期乳腺癌中，Amcenestrant的PFS结果与内分泌治疗相当

2022-09-13

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

BMC Cancer：幽门螺杆菌能影响晚期胃癌免疫治疗结局？PFS和OS均可相差3倍！

2022-08-28

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ASCO 2022 | MAINTAIN全新思路：CDK4/6抑制剂失败后跨线再战，瑞博西利仍可带来PFS获益！

2022-06-12

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ASCO 2022 | ASCENT临床大胜收官：面对「老大难」mTNBC，戈沙妥珠单抗实现OS/PFS双获益！

2022-06-09

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

J Clin Oncol：III期CROWN研究事后分析表明Lorlatinib (劳拉替尼)一线治疗较克唑替尼改善ALK阳性晚期NSCLC有或无脑转移患者的PFS

2022-05-26

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

Thorac Cancer：EGFR阳性老年NSCLC患者吉非替尼进展后单药联合继续吉非替尼可改善患者PFS

2022-05-22

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

罗氏PD-L1+TIGIT一线治疗NSCLC，期中分析发现PFS未获益，仍然期待OS终点的数据表现

2022-05-13

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

PARP 抑制剂 Rubraca (rucaparib)一线治疗晚期卵巢癌，显著延长了PFS

2022-04-04

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

Oncologist：西妥昔单抗+伊立替康+贝伐单抗联合治疗未能改善伊立替康难治性转移性结直肠癌(mCRC)的患者PFS，但可改善OS

2022-03-15

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

Liver Cancer：TACTICS研究表明在TACE基础性加用索拉非尼可改善不可切除肝细胞癌（HCC）患者的PFS，但不能改善患者的OS

2022-02-22

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

J Clin Invest：MEK抑制剂 cobimetinib联合PD-L1抑制剂 atezolizumab可延长胆道癌(BTC)的PFS

2022-01-09

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

Front Oncol：既往接受过抗血管治疗可能影响后线安罗替尼治疗晚期肺癌的PFS，但不影响OS和ORR

2021-12-25

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

Nat Med：PfSPZ疫苗对婴儿疟疾的安全性、免疫原性和有效性：一项双盲、随机、安慰剂对照的2期试验

2021-09-16

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

PFS：激光辅助治疗面部填充物并发症后，采用脂肪填充的效果甚好！

2021-03-16

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

PFS：10年随访结果出炉！记忆凝胶植入物用于隆胸或乳房再造安全有效

2021-03-16

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

PFS 翻倍！tipifarnib获FDA突破性疗法资格

2021-02-28

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

JCO：来那度胺+R-CHOP联合治疗未能显著改善ABC型DLBCL的PFS

2021-02-26

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

ASCO GU 2021: DPP4抑制剂对糖尿病合并前列腺癌患者PFS的影响

2021-02-20

jeanqiuqiu (审核中...)

前往app查看评论内容

#PFS#

PFS、ORR翻倍，死亡风险降低40%！FDA批准卡博替尼联合Opdivo一线治疗肾癌

2021-01-27

科室
- - 订阅+
  - 更多科室
工具
服务